Latest Breaking News On - Low dose rituximab - Page 1 : vimarsana.com

Following implementation of low-dose rituximab as standard of care for muscle-specific kinase–positive myasthenia gravis (MuSK-MG), a hospital evaluated the treatment’s efficacy over a 2-year period.

Neurosci lettMichael benatarShanxi medical universityMyasthenia gravis foundation of americaNeurology department of first hospitalImage creditNeuroscience lettersNeurology departmentFirst hospitalMyasthenia gravis foundationAmerica post intervention statusQuantitative myasthenia gravisMyasthenia gravis qualityLow dose rituximabMg adlMusk mg